Sunshine Biopharma (SBFM) Stock
Small biotech company developing medical treatments. Here's the price, business snapshot, and what's worth knowing about Sunshine Biopharma in September 2026.
Sunshine Biopharma Inc (ticker: SBFM) is a micro‑capitalisation biotechnology company. With a market capitalisation around $8.75m, it is likely a small, development‑stage firm where investor outcomes hinge on drug‑development progress, regulatory decisions, partnerships and access to capital. Shares can be thinly traded and prone to sharp swings on trial readouts, licensing news or fundraising announcements. Common risks include limited cash runway, the binary nature of clinical results, regulatory uncertainty and potential dilution from new equity issues. Potential upside exists if programmes advance or strategic deals are struck, but such outcomes are uncertain and not guaranteed. This summary is for general, educational purposes only and is not personalised investment advice; investors should review company filings, consider their risk tolerance and seek independent financial advice as appropriate.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Sunshine Biopharma's stock, with a target price of $178 indicating significant growth potential.
Financial Health
Sunshine Biopharma is producing good revenue and cash flow, indicating a solid financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Binary Clinical Catalysts
Trial readouts and regulatory milestones can drive large price moves; outcomes can be binary and uncertain, so performance may vary.
Financing & Dilution
Small biotechs often require additional capital. Monitor cash runway and fundraising terms, as new financing can dilute existing holders.
Partnership Potential
Collaborations or licensing deals with larger firms can materially change prospects, though they depend on positive data and successful negotiations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
